Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis.
Inflamm Bowel DisSep 1, 2026
Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the incidence of acne in 9902 patients with inflammatory bowel disease (IBD) treated with Janus kinase (JAK) inhibitors. The overall pooled incidence of acne was found to be 8.6%. Notably, acne incidence was significantly higher with upadacitinib at 12.2% compared to tofacitinib and filgotinib, and in pediatric patients at 12.2%.
Key findings
- The overall pooled incidence of acne in IBD patients on JAK inhibitors was 8.6%.
- Acne incidence was significantly higher with upadacitinib (12.2%) compared to tofacitinib (2.6%) and filgotinib (2.3%).
- Pediatric patients had a significantly higher acne incidence of 12.2% compared to adults at 7.4%.
- JAK inhibitors were associated with increased odds of acne compared to placebo (OR 2.43).
Why it matters
Understanding the incidence of acne in IBD patients treated with JAK inhibitors is crucial for clinicians to provide informed counseling and manage patient expectations regarding potential side effects.